Real-World Data Of Cancer Drugs In Elderly Could Push Regulators Toward Broader Trial Eligibility

 
• By Sarah Karlin-Smith

Medicare patients fared worse than pivotal trial populations on cancer drugs, two recent papers conclude, offering more ammunition for an increased regulatory focus on more generalizable trial populations. Current drug labels may portray an inaccurate risk-benefit calculation in older populations, which account for most cancer cases.

senior citizens playing cards
Real-world evidence shows older patients not getting trial-level benefits of cancer drugs. • Source: DCPhoto / Alamy Stock Photo

More from Real-World Evidence

More from Clinical Trials